Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference Syncromune, Inc. to Present at the 2022 BIO CEO & Investor Conference FORT LAUDERDALE, FL., Feb. 11, 2022 (BUSINESS WIRE) -- Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of intratumoral immunotherapy announced today that...
Now Enrolling: LEGION-100 Phase 2 Trial for Metastatic Castration-Resistant Prostate Cancer. Find A Location Near You ›
